-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Medtronic announced its financial results for the fourth quarter and fiscal year 2021 ending April 30, 2021.
The company reported a global revenue of US$8.
188 billion in the fourth quarter, an increase of 37% year-on-year, and an adjusted foreign currency conversion income of US$241 million, with a natural growth rate of 32%.
Medtronic’s fourth quarter results reflect the impact of the COVID-19 pandemic on the company’s selection process in April 2020, showing a strong recovery.
According to reports, according to generally accepted accounting principles (GAAP), the company’s fourth-quarter net income and diluted earnings per share (EPS) were $1.
Medtronic’s fourth-quarter revenue in the US market was US$4.
182 billion, accounting for 51% of the company’s revenue, an increase of 47%.
Medtronic’s 2021 fiscal year announced revenue of 30.
117 billion U.
According to reports, net profit for the 2021 fiscal year is 3.
606 billion U.
Reference source: Medtronic scores European approvals for 2 diabetes management devices
A few days ago, Medtronic announced its financial results for the fourth quarter and fiscal year 2021 ending April 30, 2021.
The company reported a global revenue of US$8.
Medtronic’s fourth quarter results reflect the impact of the COVID-19 pandemic on the company’s selection process in April 2020, showing a strong recovery.
According to reports, according to generally accepted accounting principles (GAAP), the company’s fourth-quarter net income and diluted earnings per share (EPS) were $1.
Medtronic’s fourth-quarter revenue in the US market was US$4.
182 billion, accounting for 51% of the company’s revenue, an increase of 47%.
Medtronic’s 2021 fiscal year announced revenue of 30.
117 billion U.
According to reports, net profit for the 2021 fiscal year is 3.
606 billion U.
S.
dollars, equivalent to 2.
66 U.
S.
dollars per share after dilution.
The non-GAAP earnings and diluted EPS for the 2021 fiscal year were US$6.
05 billion and US$4.
44, respectively, a decrease of 3%.
According to non-GAAP, diluted earnings per share increased by 2%.
Operating cash flow for the 2021 fiscal year was US$6.
24 billion.
Free cash flow for fiscal 2021 was US$4.
885 billion, which is equivalent to a free cash flow conversion rate of 81% for non-GAAP net income.
(Sina Pharmaceutical News)
Reference source: Medtronic scores European approvals for 2 diabetes management devices